One CAR T-Cell Therapy for Multiple Myeloma Tops Another in Propensity Matched Study

Published Date: 13 Dec 2024

Higher response rate, PFS, OS with cilta-cel, but ide-cel had lower rate of severe toxicity

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

2.

Ranking of the Best US Hospitals for Psychiatric Care.

3.

ICIs Show High Responses in Mediastinal B-Cell Lymphoma

4.

Specialist Referrals Are Critical for Functional High-Risk Multiple Myeloma

5.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot